QIAGEN Acquires Verogen

QIAGEN Acquires Genoox

May 12, 2025

Biotechnology

QIAGEN has signed a definitive agreement to acquire Genoox, the developer of the AI-powered Franklin clinical genomics platform, for $70 million in cash plus up to $10 million in milestone payments. The acquisition adds Genoox's cloud-based AI interpretation capabilities to QIAGEN Digital Insights, expanding QIAGEN's clinical genomics and diagnostic software offerings for labs and healthcare organizations worldwide.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

SeqOne Acquires Congenica

September 2, 2025

Software

SeqOne has acquired Congenica, a UK clinical genomics software company spun out of the Wellcome Sanger Institute, creating one of the largest pure‑play genomics software firms serving over 160 laboratories in 30+ countries. The combined business will integrate SeqOne's AI-driven NGS analysis platform with Congenica's clinical decision‑support tools to accelerate rare disease diagnoses and personalized cancer therapies while expanding SeqOne's UK presence.

Versiti Acquires Quantigen

July 10, 2023

Healthcare Services

Versiti, a national blood health organization headquartered in Milwaukee, has acquired Quantigen, a specialty laboratory and contract research organization based in Fishers, Indiana. The acquisition expands Versiti’s clinical-trials and diagnostic capabilities—adding assay development, biomarker validation, and regulatory support for preclinical and clinical research.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.

Ginkgo Bioworks Acquires Zymergen

July 25, 2022

Biotechnology

Ginkgo Bioworks (NYSE: DNA) will acquire Zymergen in an all‑stock transaction valuing Zymergen at about $300 million; Zymergen stockholders will receive 0.9179 Ginkgo shares per Zymergen share and will own ~5.25% of the combined company. The acquisition is intended to integrate Zymergen's automation, software, and data‑science capabilities and biological assets into Ginkgo's horizontal cell‑programming platform to expand capacity, capabilities, and efficiency across multiple end markets.